Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker
Abstract Objective This study evaluates the efficacy of Acu‐URO17, a highly sensitive and specific immunocytochemistry (ICC) test targeting Keratin 17, in comparison to urine cytology and UroVysion™ fluorescence in situ hybridization (FISH) for detecting bladder cancer cells in voided urine specimen...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-05-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.338 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850099904629702656 |
|---|---|
| author | Liwu Guo Alexandra Cid John Cucci Brian Kunkel Lisa Defeis Michael Matthews |
| author_facet | Liwu Guo Alexandra Cid John Cucci Brian Kunkel Lisa Defeis Michael Matthews |
| author_sort | Liwu Guo |
| collection | DOAJ |
| description | Abstract Objective This study evaluates the efficacy of Acu‐URO17, a highly sensitive and specific immunocytochemistry (ICC) test targeting Keratin 17, in comparison to urine cytology and UroVysion™ fluorescence in situ hybridization (FISH) for detecting bladder cancer cells in voided urine specimens. Methods Acupath conducted a large‐scale comparison study using 2378 voided urine specimens. Acu‐URO17, urine cytology and UroVysion™ FISH were performed on these specimens according to standardized protocols. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for Acu‐URO17 in comparison to urine cytology and UroVysion™ FISH. Results In cases diagnosed with high‐grade urothelial cancer via urine cytology, Acu‐URO17 demonstrated a sensitivity of 96% and a specificity of 82%. When compared to UroVysion™ FISH results, Acu‐URO17 exhibited a sensitivity of 97.1% and a specificity of 77.8%, surpassing the sensitivity of UroVysion™ FISH (57.1%). Notably, Acu‐URO17 showed a high NPV of 99.9%, indicating its reliability in confirming negative urine cytology results and risk‐stratifying atypical and suspicious cytology results. Conclusion The results of this large‐scale prospective study support Acu‐URO17 as a clinically relevant, non‐invasive and cost‐effective tool for detecting bladder cancer cells in voided urine specimens. Its high sensitivity, specificity and NPV make it a valuable adjunct to urine cytology and UroVysion™ FISH in the diagnosis and management of urothelial carcinoma (UC). |
| format | Article |
| id | doaj-art-b6acc645a995489dac0e53300d3a5e36 |
| institution | DOAJ |
| issn | 2688-4526 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-b6acc645a995489dac0e53300d3a5e362025-08-20T02:40:24ZengWileyBJUI Compass2688-45262024-05-015561161510.1002/bco2.338Acu‐URO17 is a highly sensitive and specific bladder cancer biomarkerLiwu Guo0Alexandra Cid1John Cucci2Brian Kunkel3Lisa Defeis4Michael Matthews5Acupath Laboratories Inc Plainview New York USAAcupath Laboratories Inc Plainview New York USAAcupath Laboratories Inc Plainview New York USAAcupath Laboratories Inc Plainview New York USAAcupath Laboratories Inc Plainview New York USAAcupath Laboratories Inc Plainview New York USAAbstract Objective This study evaluates the efficacy of Acu‐URO17, a highly sensitive and specific immunocytochemistry (ICC) test targeting Keratin 17, in comparison to urine cytology and UroVysion™ fluorescence in situ hybridization (FISH) for detecting bladder cancer cells in voided urine specimens. Methods Acupath conducted a large‐scale comparison study using 2378 voided urine specimens. Acu‐URO17, urine cytology and UroVysion™ FISH were performed on these specimens according to standardized protocols. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for Acu‐URO17 in comparison to urine cytology and UroVysion™ FISH. Results In cases diagnosed with high‐grade urothelial cancer via urine cytology, Acu‐URO17 demonstrated a sensitivity of 96% and a specificity of 82%. When compared to UroVysion™ FISH results, Acu‐URO17 exhibited a sensitivity of 97.1% and a specificity of 77.8%, surpassing the sensitivity of UroVysion™ FISH (57.1%). Notably, Acu‐URO17 showed a high NPV of 99.9%, indicating its reliability in confirming negative urine cytology results and risk‐stratifying atypical and suspicious cytology results. Conclusion The results of this large‐scale prospective study support Acu‐URO17 as a clinically relevant, non‐invasive and cost‐effective tool for detecting bladder cancer cells in voided urine specimens. Its high sensitivity, specificity and NPV make it a valuable adjunct to urine cytology and UroVysion™ FISH in the diagnosis and management of urothelial carcinoma (UC).https://doi.org/10.1002/bco2.338Acu‐URO17bladder cancercytologyfluorescence in situ hybridizationnegative predictive valueurothelial carcinoma |
| spellingShingle | Liwu Guo Alexandra Cid John Cucci Brian Kunkel Lisa Defeis Michael Matthews Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker BJUI Compass Acu‐URO17 bladder cancer cytology fluorescence in situ hybridization negative predictive value urothelial carcinoma |
| title | Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker |
| title_full | Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker |
| title_fullStr | Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker |
| title_full_unstemmed | Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker |
| title_short | Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker |
| title_sort | acu uro17 is a highly sensitive and specific bladder cancer biomarker |
| topic | Acu‐URO17 bladder cancer cytology fluorescence in situ hybridization negative predictive value urothelial carcinoma |
| url | https://doi.org/10.1002/bco2.338 |
| work_keys_str_mv | AT liwuguo acuuro17isahighlysensitiveandspecificbladdercancerbiomarker AT alexandracid acuuro17isahighlysensitiveandspecificbladdercancerbiomarker AT johncucci acuuro17isahighlysensitiveandspecificbladdercancerbiomarker AT briankunkel acuuro17isahighlysensitiveandspecificbladdercancerbiomarker AT lisadefeis acuuro17isahighlysensitiveandspecificbladdercancerbiomarker AT michaelmatthews acuuro17isahighlysensitiveandspecificbladdercancerbiomarker |